Cite
MLA Citation
Patrick Wen et al.. “ACTR-51. PHASE 2 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND CLINICAL ACTIVITY OF PI3K/MTOR INHIBITOR GDC-0084 GIVEN TO GLIOBLASTOMA (GBM) PATIENTS WITH UNMETHYLATED O6-METHYLGUANINE-METHYLTRANSFERASE PROMOTER STATUS.” Neuro-oncology, vol. 20, n.d., p. vi23. http://access.bl.uk/ark:/81055/vdc_100095508705.0x000012